1	The landscape of paediatric infectious disease
2	exposure in a rural sub-Saharan Africa setting
3	in Kilifi, Kenya: longitudinal serological
4	analysis over two decades and priorities for
5	future vaccine development
6 7 8 9	Deirdre F Foley, MD ^{*#1,2,3} , Timothy K Chege, MSc ^{#1, 4} , Joyce Kabagenyi, MSc ^{#1} , Karen McCarthy, MD ^{1,2} , Elijah T Gicheru, Dip ¹ , Nelson Kibinge, PhD, Angela W Maina, MSc ¹ , Jacqueline M Waeni, PhD ¹ , Ralf Clemens PhD ⁵ , Sue-Ann Costa Clemens, PhD ^{4,6} , James Tuju, PhD ¹ , Charles J Sande, PhD ^{*1,7}
10	
11	1. KEMRI-Wellcome Trust Research Programme, Kilifi, Kenya
12	2. Department of Continuing Education, University of Oxford, Oxford, UK
13	3. Children's Health Ireland – Crumlin, Dublin, Ireland
14	4. Institute of Global Health, University of Siena, Siena, Italy
15	5. International Vaccine Institute, Seoul, Republic of Korea
16	6. Oxford Vaccine Group, University of Oxford, Oxford, UK
17	7. Nuffield Department of Medicine, University of Oxford, Oxford, UK
18	
19	
20	* Correspondence to:
21	
22 23	Dr Deirdre J Foley, Department of Peadiatric Infectious Disease, Children's Health Ireland at Crumlin, Cooley Road, Dublin, D12N512, Ireland (<u>deirdrefoley731@gmail.com</u>)
24	
25 26	Dr. Charles Sande, Bioscience Department, KEMRI-Wellcome Trust Research Programme, Kilifi, Kenya P.O. Box 230 - 80108 (csande@kemri-wellcome.org)
27	#contributed equally
28	NOTE: This preprint reports new research that has not been certified by peer review and should not be used to guide clinical practice.

29 Abstract

30 Background

31

32 The paucity of data on the contemporary causes of serious infection among the world's most

- 33 vulnerable children means the landscape of emerging paediatric infectious disease remains
- 34 largely undefined and out of focus on the global vaccine research and development agenda.
- 35

36 Methods

37

We aimed to partially define the paediatric infectious disease landscape in a typical lowincome setting in sub-Saharan Africa in Kilifi, Kenya by simultaneously estimating antibody prevalence for 38 infectious diseases using a longitudinal birth cohort that was sampled between 2002 and 2008 and a paediatric inpatient cohort that was sampled between 2006 and 2017.

43

44 Findings

45

46 Among the infectious diseases with the highest antibody prevalence in the first year of life 47 were vaccine-preventable diseases such as RSV (57.4%), mumps (31.5%) and influenza H3N2 (37.3%). Antibody prevalence for *Plasmodium falciparum* shifted substantially over time, 48 49 from 47% in the mid 2000s to 13% approximately 10 years later corresponding to a documented decline in parasite transmission. A high prevalence of antibodies was also 50 51 observed in the first year of life for infections for which no licenced vaccines are currently available, including norovirus (34.2%), cytomegalovirus (44.7%), EBV (29.3%) and coxsackie B 52 53 virus (40.7%). The prevalence to antibodies to vaccine antigens in the local immunisation schedule was generally high but varied by antigen. 54

55

56 Interpretation

The data show a high and temporally stable infection burden of RSV, mumps and influenza,
providing a compelling evidence base to support progress towards the introduction of these
vaccines into the local immunization schedule. The high prevalence of norovirus, EBV, CMV

- 60 and Coxsackie B provide rationale for increased vaccine research and development
- 61 investment.
- 62 Funding
- 63 This research was funded by the Wellcome Trust (grant no. WT105882MA).

64 Introduction

Though the national under-five mortality rate in Kenya and many other low- and middle-65 income countries has declined by almost two-thirds since 1990, sub-Saharan Africa still 66 reports the highest childhood mortality rate, and targets for the reduction of global childhood 67 mortality remain unmet.¹ In the first two decades of this century there have been numerous 68 69 reports of newly emergent infectious diseases that have caused major human outbreaks including Rift Valley Fever virus,² pandemic and endemic coronaviruses,³ Chikungunya virus,⁴ 70 Ebola virus⁵ and Zika virus⁶ virus among others. While some of these outbreaks have attracted 71 global attention and have been the focus of co-ordinated international vaccine development 72 73 efforts, many other pathogens with more localised transmission phenotypes in low-income 74 countries have attracted less investment in vaccine research and development. These 75 pathogens continue to exert a considerable and often covert morbidity and mortality burden 76 among the world's poorest populations.⁷

Many infections such as Rift-Valley Fever, West Nile and Usutu virus, among others, occur primarily in sub-Saharan Africa and cause widespread infections with potentially high case fatality rates. No vaccines currently exist for these and similar high-consequence pathogens that are predominantly localised to low-income countries (LICs). In addition to these major infections, there are many other vaccine-preventable diseases circulating among populations in LICs that continue to exert a serious toll on the health and well-being of these populations, but whose priority for introduction to national immunization schedule remains low.

To make the case for both vaccine introduction and increased investment in vaccine research 84 against locally relevant pathogens, estimates of the infection burden attributable to specific 85 pathogens in vulnerable populations is imperative. To assess this burden, we determined 86 population-level antibody prevalence for 38 distinct infectious disease pathogens in young 87 88 children from a low-income setting in sub-Saharan Africa. Using multi-target serological 89 analysis of two paediatric cohorts in rural Kenya, we define the prevailing infectious disease 90 landscape in young infants and children over the last two decades and propose priorities for 91 vaccine development and introduction.

Methods 93

94 Study design and participants

95 This study was conducted in Kilifi County Kenya, a rural community on the Kenyan Coast. We used two study cohorts to measure disease of 38 infectious disease pathogens in Kenyan 96 97 infants and young children. The first was a longitudinal birth cohort (Kilifi Birth Cohort, 'KBC') recruited between 2002 and 2005 from which cord blood was collected at birth, followed by 98 99 repeated serum sampling at approximate three-month intervals until children were aged 100 about thirty months of age (Supplementary figure 1). The second was an inpatient cohort 101 comprising of paediatric inpatients admitted to Kilifi County Hospital between 2006 and 2017 102 with a variety of infectious and non-infectious illnesses (Supplementary figure 2). Serum from 103 each child was assayed for antibodies against the same set of infectious disease pathogens. 104 All data are presented using anonymized codes that are delinked from personally identifiable 105 participant data. This study was conducted in accordance to Good Clinical Laboratory practice 106 principles and was approved by the Scientific Ethics Research Unit of the Kenya Medical 107 Research Institute.

108

109 Procedures

110 Pathogen-specific antibodies were measured using a customized protein microarray designed 111 to quantify serum IgG to a range of common and emerging infectious diseases. The complete set of pathogens, strains and antigens that were tested on this platform are listed in 112 113 Supplementary table 1. Data generated on the microarray was extensively validated by relating changes in antibody level to known timings of vaccination or natural infection. 114 115 Increases in antigen-specific antibodies in the birth cohort time series were confirmed to 116 contemporaneously coincide with independent laboratory diagnoses based on PCR or 117 enzyme immunoassays. An example of this validation approach is illustrated in Supplementary figure 3. Microarray slides were produced by the deposition of two 100pl 118 droplets containing 1ug/ml of the protein antigens onto epoxy-coated polished glass slides by 119 120 non-contact printing using an Aj003S Arrayjet Sprint microarrayer. Each slide was partitioned 121 into 24 identical mini arrays onto which the complete set of antigens to be assayed were

122 identically printed. Printed slides were allowed to dry at ambient temperature and then 123 placed at 4°C for long-term storage. Prior to sample processing, slides were scanned on a 124 Genepix 4300A fluorescent scanner to obtain background slide fluorescence that would later 125 be subtracted from the final microarray data set to correct for non-specific fluorescence. Slides were then loaded onto hybridization cassettes, washed three times with phosphate 126 127 buffered saline, and incubated with a blocking buffer comprising phosphate buffered saline 128 supplemented with Tween-20 and 5% bovine serum albumin for an hour at 37°C. A one in 129 thirty dilution of human sera was prepared using phosphate buffered saline supplemented with tween-20 and 5% bovine serum albumin. Different serum samples that were pre-130 131 processed in this manner were then aliquoted into distinct mini-arrays and incubated at room 132 temperature for three hours. The slides were then washed thrice, after which a one in four 133 hundred dilution of polyclonal goat anti-human IgG conjugated to Alexa Fluor-647 was added 134 to each mini-array and incubated at room temperature for two hours. The slides were then 135 washed three times and rinsed with Milli-Q water, after which they were scanned using a 136 Genepix 4300A scanner at PMT setting 600 and 100% power. The data was exported to R 137 version 3.6.2 for analysis. The design of the microarray chip and the analytical sample 138 workflow are shown in Supplementary figure 4.

139

140 Statistical analysis

141 In the birth cohort, antigen-specific seroprevalence was determined by calculating the change in antibody level between successive timepoints in the longitudinal time series. The 142 143 serological definition of an infection was an increase of \geq 4000 antibody units (expressed as 144 normalized median fluorescence intensities, MFI) between two serial timepoints and 145 sustained in the subsequent two time points. An example of these serologically defined infections is illustrated in Supplementary figure 3 and in our previously published work⁸. Age-146 147 specific seroprevalence for different infections was determined by calculating the proportion 148 of children with serologically defined infections at 12 and 24 months and of age. In the 149 inpatient cohort, seroprevalence estimates at 12 months of age were calculated by first 150 partitioning the antibody data into three-monthly age strata and then identifying a 151 seronegative age stratum at the nadir of maternal antibody decline for each antigen. A

serological response threshold for each antigen was then defined as the mean antibody level 152 153 in the seronegative stratum plus three standard deviations. This threshold was applied to 154 calculate antibody prevalence at subsequent time points. Differences in seroprevalence 155 between the birth and inpatient cohorts were measured using the chi-square 2-sample test for equality of proportions. To visualize age-related changes in antibody level against vaccine 156 antigens in the birth cohort, we used linear spline regression modelling. The non-linear 157 relationship between age and antibody titre was characterized by partitioning the predictor 158 159 variable (age) into six-monthly segments in which the relationship between age and antibody 160 titre was presumed to be linear. Piecewise linear regression models joined at 6-monthly 161 changepoints starting at birth were developed using the 'stats' package available in R.

162 Results

163 To estimate the seroprevalence of antibodies against 38 infectious disease pathogens over 164 the first two decades of this century in children in Kilifi, Kenya, we assayed a total of 1,134 165 serum samples from two cohorts spanning a period of 15 years (January 2002 to June 2017). 166 Local antibody prevalence in the first of these cohorts, the longitudinal Kilifi Birth Cohort (KBC) was estimated using serial samples collected from 124 children who were recruited at birth. 167 168 This group was recruited between January 2002 and November 2008 and prospectively sampled at three-monthly intervals for approximately 30 months. An average of eight serum 169 170 samples were collected from each child in the longitudinal series, resulting in a total collection 171 of 958 serum samples (table 1). The second cohort was a paediatric inpatient (IP) cohort in 172 which a single admission sample was collected from 176 children, who ranged between one 173 day and 57 months of age and who had been admitted to hospital with a variety of medical 174 conditions (table 1). A summary of the sampling frame for both the longitudinal and inpatient 175 cohorts is shown in Supplementary figures 1 and 2 respectively.

Antibody prevalence for all 38 infectious diseases featured on the protein array was estimated
at 12- and 24-months age in the birth cohort as shown in figure 1. Overall seroprevalence
ranged from 0% for ebolavirus and yellow fever virus, to 57% for Respiratory Syncytial Virus
(RSV) in the first year of life. To facilitate detailed analysis, antibody data were further
stratified into four groups as follows: high prevalence infections (defined as seroprevalence ≥

181 25%) that were vaccine-preventable, but not currently included on the Kenya Expanded 182 Programme on Immunization (EPI) schedule (i.e. high prevalence, not on EPI or HP-NEPI), high 183 prevalence diseases for which no licensed vaccines exist (high prevalence, no vaccine or HP-184 NV), low prevalence (LP) infections (seroprevalence <25%) regardless of vaccine availability, 185 and diseases whose vaccines are current included in the Kenya EPI (i.e. Established in EPI or 186 EEPI).

187 RSV, Mumps virus and Influenza virus H3N2 satisfied the HP-NEPI classification criteria in both 188 the longitudinal and inpatient cohorts, with 12-month antibody seroprevalence of 57.4% and 56% respectively for RSV, 32% and 31% respectively for Mumps virus and 37% and 25% 189 190 respectively for H3N2 influenza. By 24 months of age, RSV seroprevalence had increased to 191 76.5% in the longitudinal cohort, while Mumps and H3N2 seroprevalence at this time point 192 was 44.4% and 60.9% respectively (table 1 and figure 1). VZV seroprevalence partially satisfied 193 these criteria, with 28% seroprevalence in the longitudinal cohort, later declining to 15% in 194 the inpatient cohort. A similar pattern of antibody prevalence decline was observed for 195 Plasmodium falciparum, whose 12-month seroprevalence the longitudinal cohort was 47%, 196 declining to 13% in the inpatient cohort (figure 1 and figure 3). Two additional infections, Streptococcus pneumoniae and Rotavirus were initially categorized in the HP-NEPI with 197 198 estimated 12-month seroprevalence rates of 36% and 45.9% respectively in the longitudinal 199 cohort (figure 1 and table 2) and 18% and 27% in the inpatient cohort (figure 3) but later 200 transitioned to the EEPI category when their respective vaccines were introduced to the local 201 EPI schedule in 2011 and 2014 respectively.

202 The HP-NV group for which no licensed vaccines are currently available was made up of four infectious diseases, whose 12-month seroprevalence estimates were consistently above 25% 203 204 in both cohorts. Norovirus (34% in both the longitudinal and inpatient cohorts), 205 Cytomegalovirus (44.7% longitudinal cohort, 29% inpatient cohort), Coxsackie B virus (40.7% longitudinal cohort, 25% inpatient cohort) and Epstein-Barr virus (29% in both the longitudinal 206 207 and inpatient cohorts) are displayed in table 2 and figure 3. For both HP-NEPI and HP-NV 208 groups, these seroprevalence estimates rose substantially at 24 months of age (figure 1, table 209 2 and figure 3). Several infections including Klebsiella pneumoniae, Helicobacter pylori and 210 Mycoplasma pneumonia exhibited high antibody seroprevalence above the 25% threshold in

the inpatient cohort but lower seroprevalence below this level in the longitudinal cohort(figure 3).

The low prevalence (LP) group featured a variety of viral pathogens as shown in table 2, 213 214 including flaviviruses such as Dengue viruses, Zika virus, Chikungunya virus, Ebola virus, West-215 Nile virus, tick-borne encephalitis, and yellow fever virus. Except for dengue, all other flaviviral 216 infections had antibody prevalence below 5% at 12 months of age as shown in table 2. Twelve-217 month seroprevalence for dengue viruses ranged from 7% for dengue virus type 3 in the longitudinal cohort and 9% in the inpatient cohort, to 22.3% for dengue virus type 1 in the 218 longitudinal cohort and 15% in the inpatient cohort. Among the infections studied in the LP 219 220 group were seven Influenza H1N1 viruses, including the 1918 and 2009 pandemic virus 221 strains. The seroprevalence of antibodies against all H1N1 Influenza A viruses, including the 222 pandemic strains, was consistently below 15% at 12 months of age in both cohorts (figure 3). 223 Other LP infections included hepatitis A, *Staphylococcus aureus*, Usutu virus, Rift valley fever 224 virus, Astrovirus, Enterovirus 71 virus and Leishmania donovani, with antibody prevalence 225 estimates at or below 3% by the end of the first year of life.

226 The EEPI group included infections whose respective vaccines are currently included in the 227 Kenya EPI and showed consistently high seroprevalences. In the longitudinal cohort, we 228 evaluated the antibody response against three antigenic targets in the pentavalent vaccine formulation and found antibody prevalence for Corynebacterium diphtheriae, Bordetella 229 230 pertussis and Hepatitis B virus of 70.8%, 56.6% and 46% respectively at 12 months of age, 231 rising to 80.5%, 66.1% and 53.6% respectively by 24 months of age (figure 2). We also 232 examined temporal changes in antibody level to determine whether the timing of the antibody response to these antigens was consistent with vaccination or natural exposure. For 233 234 all three antigens, there was a rapid rise in antibody level within the first three months of life, 235 coinciding with the prescribed timing of 3 pentavalent vaccine doses on the local EPI schedule 236 (6 weeks, 10 weeks, and 14 weeks) as seen in figure 2. The peak population-level antibody 237 titre occurred shortly after the final dose, followed by a variable temporal pattern of antibody 238 decay that was observed post peak (figure 2). Pertussis-specific titres remained stable over time, while antibodies targeting the diphtheria toxin and hepatitis B surface antigen decayed 239 240 at a faster rate during follow-up but remained significantly above cord blood titre levels

despite the wane. Comparison of these antibody dynamics with those of unrelated antigens
that are not part of the local vaccination schedule (Ebolavirus, EBV and H1N1 influenza (1999)
virus) showed that temporal kinetics of these alternative antibody specificities were antigen-

- 244 specific and did not correspond to the scheduled timing of the three pentavalent vaccine
- 245 doses (figure 2).
- 246

247 Discussion

248 The main objective of this study was to describe the contemporary landscape of paediatric 249 infectious disease among children in a rural, sub-Sharan African setting in Kenya by estimating the antibody prevalence for a range of infectious diseases. Our data demonstrate a 250 251 considerable and sustained local infection burden from several vaccine preventable diseases 252 in the first year of life including RSV, Mumps virus and H3N2 influenza. Just under 60% of 253 infants in both the longitudinal birth cohort and the inpatient cohort had detectable serum 254 antibody against RSV at twelve months of age, rising to around 80% seroprevalence by their 255 second birthday. RSV is the most important cause of severe childhood respiratory illness in 256 the world⁹, with the mortality burden being disproportionately borne by children in lowresource settings¹⁰ due to poor healthcare infrastructure for the supportive care of critically 257 258 ill children, including supplemental oxygen and mechanical ventilation. A new maternal 259 vaccine against RSV with a reported efficacy of 82% against severe disease in the first 3 months¹¹ of life has recently been approved by the Food and Drug administration (FDA) in the 260 United States¹² and the European Medicines Agency¹³. While extensive surveillance studies 261 262 in the United States and Europe have long established the health and economic burden attributable to RSV in those settings, similar data in lower resource settings have been sparse. 263 264 The data presented here indicates a significant infection burden due to RSV among infants in sub-Saharan Africa and contributes to the evidence base that will inform decisions on 265 266 whether to introduce newly licensed maternal RSV vaccines in these settings. Our data aligns with longitudinal birth cohort studies in the United States which demonstrated 68% and 82% 267 antibody prevalence against RSV at the end of the first and second years of life respectively.¹⁴ 268

269

Around a third of infants in both study cohorts had serologic evidence of mumps infection at
12 months of age rising to about 44% by their second birthday. Mumps is a highly contagious

febrile infection, that can lead to potentially debilitating sequelae including meningitis, hydrocephalus, pancreatitis, and hearing loss.¹⁵ A safe and highly effective vaccine against mumps has been available since the 1960s, initially as a stand-alone vaccine and later as a multivalent formulation comprising measles, mumps, and rubella virus antigens.¹⁶ Our data indicate a substantial local burden of natural mumps infection in Kenyan children and provide rationale for vaccine introduction in the local paediatric immunization schedule to address this sizeable infection burden.

279

Our analysis of influenza infection in infants and young children found a high prevalence of 280 281 antibodies to H3N2 influenza and a low prevalence of H1N1-specific antibodies. We found 282 uniformly low prevalence of antibodies specific to broad range of H1N1 strains, including the 283 1918 and 2009 pandemic strains as well as seasonal H1N1 strains isolated in 1933, 1934, 1977, 284 1999 and 2006. These observations align with results from previous studies of African 285 children, where the incidence of seasonal H1N1 influenza infection in infancy was reported to be around 6 per 10,000 infants.^{17,18} We identified a much greater prevalence of antibodies 286 287 against the H3N2 strain of seasonal influenza, with antibody prevalence remaining above 25% 288 in both study cohorts at 12 months of age. Paediatric influenza vaccines licenced for use in children over six months have been available for several years now. Although many studies in 289 290 this population have demonstrated a clear benefit of vaccination against severe disease,¹⁹ 291 vaccine evaluation studies have shown modest vaccine effectiveness of seasonal influenza vaccination in children, particularly against the H3N2 strain of the virus .^{20,21} 292

293

294 For some pathogens, we found a shifting pattern of antibody prevalence over time. For 295 example, antibody prevalence for *Plasmodium falciparum* was initially 47% in the longitudinal 296 cohort which was sampled between 2002 and 2008 but later declined to 13% in the inpatient 297 cohort (sampled between 2006 and 2017). This decay in antibody prevalence corresponds 298 with documented evidence of a local decline in malaria disease burden in infants during that period. The proportion of infants admitted to hospital in Kilifi Kenya with a positive P. 299 *falciparum* test declined from over 50% in the early 2000s to less than 10% by 2014.²² Our 300 301 data therefore largely confirm these temporal changes in the local paediatric disease burden 302 attributable to falciparum malaria and indicates that this serological approach would be 303 useful in measuring future changes in disease trends at the population level.

304

305 We also detected a change in antibody prevalence for two infections whose vaccines were 306 not part of the local immunization schedule at the time of sampling the longitudinal cohort, 307 but that were later introduced soon after the initiation of inpatient cohort sampling. The 308 decline in prevalence of antibodies against S. pneumoniae from 36% in the longitudinal cohort to 18% in the inpatient cohort and from 36.3% to 27% for Rotavirus, corresponds with the 309 introduction of highly effective vaccines for these targets into the local EPI schedule in 2011²³ 310 and 2014²⁴ respectively. 311

312

313 A limitation of our study is that the demographics of the inpatient cohort differ from the birth 314 cohort in that the median age is younger (7.2 months), with a range of 0-5 years. The birth 315 cohort were tracked at regular intervals to 24 months of age mapping seroprevalence trends 316 over the first two years of life. While the inpatient group represents a contemporary glimpse 317 into childhood seroprevalence of infection, direct comparison of data between the cohorts 318 should be interpreted in a conservative manner. Group B streptococcus antibody was not 319 included as a for target for serological analysis within this study and represents a potential future 320 research opportunity.

321

Our study found a high antibody prevalence for several infections against which no licensed 322 323 vaccines currently exist. Notable among these were EBV, the cause of infectious mononucleosis²⁵ and malignant Burkitt's lymphoma,²⁶ CMV which causes congenital infection 324 325 associated with severe neurological sequelae including sensorineural hearing loss and 326 cognitive impairment^{27,28} and Coxsackie B virus whose symptoms range from acute febrile 327 manifestations to myocarditis.²⁹ In addition to these infections, we found that more than a 328 third of infants in both study cohorts had antibodies against Norovirus, a highly contagious 329 cause of acute severe gastroenteritis.²⁵ Since the introduction of effective rotavirus vaccines, norovirus has become the leading cause of vomiting and diarrhea in many countries around 330 the world.³⁰ By establishing the considerable burden of disease attributable to these 331 infections, our data supports the case for increased investment in vaccine research and 332 333 development as well as broader surveillance in diverse populations, particularly in low 334 resource settings. In contrast to these infections, we found a low prevalence of antibodies to

a range of infections, including most flaviviruses, *Staphylococcus aureus*, Enterovirus 71 and *Leishmania donovani*.

337

338 Finally, our assessment of the temporal kinetics of antibodies specific to three vaccine antigens in the pentavalent vaccine showed a population-level increase in the titre of 339 antibodies against diphtheria, Hepatitis B and Bordetella pertussis that coincided with the 340 prescribed age for pentavalent vaccine dosing at 6, 10 and 14 weeks. The estimated 341 342 seroprevalence at 12 months was highest for diphtheria at around 71%, followed by pertussis and hepatitis B at 56.7% and 46% respectively. Since these antigens are delivered in a single 343 344 formulation, the variable antibody prevalence estimates might be explained by several factors 345 including differential background rates natural infection, varying propensities for immune 346 stimulation and differential rates of post-vaccination antibody decay. Even by adopting the most sanguine interpretation of these data, that the estimated seroprevalence of diphtheria 347 348 (71%) reflects true vaccine coverage, the data indicate that a substantial proportion of infants 349 remain unprotected by the end of infancy, thereby providing a justification for more detailed 350 assessment of suboptimal immunization in children from such settings.

351

352 In summary, our research advocates for the urgent introduction of vaccines against RSV, 353 mumps and seasonal influenza into the local immunization schedule. In the case of RSV, 354 maternal vaccination should be paired long-acting immunoprophylactic monoclonal antibodies to provide extended protection to the end of infancy following the decay of 355 356 maternal antibodies. In conclusion, our study is the first major multi-target sero-surveillance 357 study in African children and the results provide the evidence base to reconsider priorities for 358 the development and introduction of vaccines for a low resource setting in sub-Saharan 359 Africa.

- 360
- 361
- 362

References 363

364 Sharrow D, Hug L, You D, et al. Global, regional, and national trends in under-5 1. 365 mortality between 1990 and 2019 with scenario-based projections until 2030: a systematic 366 analysis by the UN Inter-agency Group for Child Mortality Estimation. The Lancet Global 367 *health* 2022; **10**(2): e195-e206.

368 Nanyingi MO, Munyua P, Kiama SG, et al. A systematic review of Rift Valley Fever 2. 369 epidemiology 1931-2014. Infect Ecol Epidemiol 2015; 5: 28024.

370 3. Chathappady House NN, Palissery S, Sebastian H. Corona Viruses: A Review on SARS, 371 MERS and COVID-19. Microbiol Insights 2021; 14: 11786361211002481.

372 4. Chinedu Eneh S, Uwishema O, Nazir A, et al. Chikungunya outbreak in Africa: a review 373 of the literature. Ann Med Surg (Lond) 2023; 85(7): 3545-52.

374 Jacob ST, Crozier I, Fischer WA, 2nd, et al. Ebola virus disease. Nat Rev Dis Primers 5. 375 2020; 6(1): 13.

376 6. Baud D, Gubler DJ, Schaub B, Lanteri MC, Musso D. An update on Zika virus infection. 377 Lancet (London, England) 2017; **390**(10107): 2099-109.

378 Coates MM, Ezzati M, Robles Aguilar G, et al. Burden of disease among the world's 7. 379 poorest billion people: An expert-informed secondary analysis of Global Burden of Disease 380 estimates. PloS one 2021; 16(8): e0253073.

381 Ohuma EO, Okiro EA, Ochola R, et al. The natural history of respiratory syncytial virus 8. 382 in a birth cohort: the influence of age and previous infection on reinfection and disease. 383 American journal of epidemiology 2012; **176**(9): 794-802.

384 Shi T, McAllister DA, O'Brien KL, et al. Global, regional, and national disease burden 9. 385 estimates of acute lower respiratory infections due to respiratory syncytial virus in young 386 children in 2015: a systematic review and modelling study. Lancet (London, England) 2017.

387 10. Nair H, Nokes DJ, Gessner BD, et al. Global burden of acute lower respiratory infections 388 due to respiratory syncytial virus in young children: a systematic review and meta-analysis. 389 Lancet (London, England) 2010; 375(9725): 1545-55.

390 11. Kampmann B, Madhi SA, Munjal I, et al. Bivalent Prefusion F Vaccine in Pregnancy to 391 Prevent RSV Illness in Infants. The New England journal of medicine 2023; 388(16): 1451-64.

392 FDA. FDA Approves First Vaccine for Pregnant Individuals to Prevent RSV in Infants. 12. 393 2023. <u>https://www.fda.gov/news-events/press-announcements/fda-approves-first-vaccine-</u> 394 pregnant-individuals-prevent-rsv-infants (accessed 29 August 2023 2023).

395 13. EMA. First RSV vaccine to protect infants up to 6 months of age and older adults. 2023. 396 https://www.ema.europa.eu/en/news/first-rsv-vaccine-protect-infants-6-months-age-

397 older-

adults#:~:text=EMA%20has%20recommended%20granting%20a,respiratory%20syncytial%2 398 399 Ovirus%20(RSV). (accessed 29 August 2023 2023).

- 400 Glezen WP, Taber LH, Frank AL, Kasel JA. Risk of primary infection and reinfection with 14. 401 respiratory syncytial virus. American journal of diseases of children (1960) 1986; 140(6): 543-402 6.
- 403 Rubin S, Eckhaus M, Rennick LJ, Bamford CG, Duprex WP. Molecular biology, 15. 404 pathogenesis and pathology of mumps virus. J Pathol 2015; 235(2): 242-52.

405 Kowalzik F, Faber J, Knuf M. MMR and MMRV vaccines. Vaccine 2018; 36(36): 5402-7. 16. 406 Fell DB, Johnson J, Mor Z, et al. Incidence of laboratory-confirmed influenza disease 17. 407 among infants under 6 months of age: a systematic review. BMJ open 2017; 7(9): e016526.

408 18. Onyango CO, Njeru R, Kazungu S, et al. Influenza surveillance among children with 409 pneumonia admitted to a district hospital in coastal Kenya, 2007-2010. The Journal of 410 infectious diseases 2012; 206 Suppl 1: S61-7.

411 Olson SM, Newhams MM, Halasa NB, et al. Vaccine Effectiveness Against Life-19. 412 Threatening Influenza Illness in US Children. Clinical infectious diseases : an official publication 413 of the Infectious Diseases Society of America 2022; 75(2): 230-8.

- 414 Chiu SS, Kwan MYW, Feng S, et al. Influenza Vaccine Effectiveness Against Influenza 20. 415 A(H3N2) Hospitalizations in Children in Hong Kong in a Prolonged Season, 2016/2017. The 416 Journal of infectious diseases 2018; **217**(9): 1365-71.
- 417 21. Hood N, Flannery B, Gaglani M, et al. Influenza Vaccine Effectiveness Among Children: 418 2011-2020. Pediatrics 2023; 151(4).
- 419 22. Mogeni P, Williams TN, Fegan G, et al. Age, Spatial, and Temporal Variations in 420 Hospital Admissions with Malaria in Kilifi County, Kenya: A 25-Year Longitudinal Observational 421 Study. PLoS medicine 2016; 13(6): e1002047.

422 23. Hammitt LL, Akech DO, Morpeth SC, et al. Population effect of 10-valent 423 pneumococcal conjugate vaccine on nasopharyngeal carriage of Streptococcus pneumoniae 424 and non-typeable Haemophilus influenzae in Kilifi, Kenya: findings from cross-sectional 425 carriage studies. The Lancet Global health 2014; 2(7): e397-405.

426 24. Wandera EA, Mohammad S, Bundi M, et al. Impact of rotavirus vaccination on 427 rotavirus hospitalisation rates among a resource-limited rural population in Mbita, Western 428 Kenya. Tropical medicine & international health : TM & IH 2018; 23(4): 425-32.

429 25. Lopman BA, Steele D, Kirkwood CD, Parashar UD. The Vast and Varied Global Burden 430 of Norovirus: Prospects for Prevention and Control. *PLoS medicine* 2016; **13**(4): e1001999.

432	<u>Tables</u>			
433				
434			Longitudinal cohort (KBC)	Inpatient cohort (IP)
435	_	Number of children in cohort	124	176
436	_	Recruitment dates	28 th Jan 2002- 25 th Nov 2008	20 th Dec 2006 – 10 th June 2017
437 438		Average number of samples per child (range)	8 (5 – 11)	1
439	_	Median age in months at recruitment (range)	0	7.2 (0-57)
440 441		Median age at exit from cohort (range)	23 (8.3 – 30.2)	NA
441		Total serum samples tested	958	176

443 Table 1

444 Demographics and patient sampling methods of both cohorts within the study.

Each participant in the longitudinal birth cohort had cord blood collected at birth, followed 445

446 by repeated serum sampling at three-monthly intervals. The inpatient cohort (IP) had serum

447 from each child sampled at single time point during a hospital admission and assayed for

448 antibodies against the same set of infectious disease pathogens.

Antigen code	Pathogen	Seroprevale nce at 12 months (95% CI)	Seroprevale nce at 24 months (95% CI)	Group
EBOVZAIRE	Ebola virus – Zaire strain	0 (0-0)	0 (0-0)	LP
YFVNS1A	Yellow fever virus	0 (0-0)	1.1 (0-3.2)	LP
JEVNS1	Japanese Encephalitis virus	0.8 (0-2.4)	2.5 (0-5.3)	LP
TBENS1	Tick-borne encephalitis virus	1.6 (0-3.9)	2.5 (0-5.3)	LP
HEPAV	Hepatitis A virus	0.8 (0-2.4)	2.7 (0-5.6)	LP
H1N1_HA.1934	Influenza A (H1N1 1934)	1.7 (0-3.9)	2.7 (0-5.6)	LP
SAURENTOXA	Staphylococcus aureus	0.8 (0-2.4)	2.7 (0-5.7)	LP
H1N1_HA.2006	Influenza A (H1N1 2006)	1.7 (0-4.1)	2.8 (0-5.9)	LP
H1N1_HA.1977	Influenza A (H1N1 1977)	1.7 (0-4.1)	2.8 (0-5.9)	LP
CCHIKVE1	Chikungunya virus	0.8 (0-2.5)	2.9 (0-6.1)	LP
ASTROVT1	Astrovirus	2.5 (0-5.3)	3.5 (0.1- 6.8)	LP
H1N1_HA.1999	Influenza A (H1N1 1999)	2.6 (0-5.5)	3.7 (0.1- 7.2)	LP
WNVNS1	West Nile virus	2.4 (0-5.1)	4.1 (0.5- 7.6)	LP
LEISHDON	Leishmania donovani	3.4 (0.1- 6.6)	4.3 (0.5- 7.9)	LP
RVFGC	Rift valley fever virus	1.7 (0-3.9)	4.8 (0.6- 8.8)	LP
USUVNS1	Usutu virus	1.6 (0-3.8)	5.2 (1-9.1)	LP
H1N1_HA.1933	Influenza A (H1N1 1933)	1.7 (0-4)	5.4 (1.1- 9.5)	LP
EV71ETOX	Enterovirus 71	3.4 (0.1- 6.5)	5.4 (1.1- 9.6)	LP

H1N1_HA.1918	Influenza A (H1N1 1918)	3.4 (0.1- 6.6)	6.2 (1.6- 10.6)	LP
H1N1_HA.2009	Influenza A (H1N1 2009)	4.3 (0.5- 7.9)	7.3 (2.3- 12.1)	LP
ZIKVNS1	Zika virus	3.4 (0.1- 6.6)	7.5 (2.3- 12.4)	LP
STYPHH	Salmonella enterica (serovar typhi)	5 (1-8.8)	9.6 (4-14.8)	LP
HSV1EXT	Herpes simplex virus 1	2.7 (0-5.6)	10.2 (4.3- 15.8)	LP
DENG3NS1	Dengue virus Type 3	7 (2.2-11.5)	10.9 (4.9- 16.6)	LP
CHLAMPNEU	Chlamydia pneumoniae	6.7 (2.1- 11.1)	11.5 (5.4- 17.2)	LP
TOXOPGON	Toxoplasma gondii	6.9 (2.2- 11.4)	12.4 (6.1- 18.4)	LP
PARVO1	Parvovirus 1	7.7 (2.7- 12.4)	14.5 (7.6- 20.8)	LP
NGARIV	Ngari virus	8.5 (3.3- 13.4)	15.8 (8.8- 22.2)	LP
CLOSTDEF	Clostridium difficile	17.2 (9.8- 23.9)	23.9 (14.9- 31.8)	LP
DENG4NS1	Dengue virus Type 4	15.9 (8.7- 22.6)	24.7 (15.5- 32.9)	LP
VZV	Varicella zoster virus	28.3 (19.3- 36.3)	32.3 (22.9- 40.6)	HP-NEPI
DENG1NS1	Dengue virus Type 1	22.3 (13.8- 29.9)	33.8 (23.4- 42.8)	LP
EBV	Epstein-Barr virus	29.3 (20.2- 37.3)	41.9 (31.7- 50.6)	HP-NV
MUMPSV	Mumps virus	31.5 (22.4- 39.5)	44.4 (34.1- 53)	HP-NEPI
KLEBPNEU	Klebsiella pneumoniae	32.4 (22.7- 40.9)	44.6 (33.7- 53.7)	HP-NV
HPYLOR	Helicobacter pylori	35 (25.1- 43.6)	45.6 (34.9- 54.6)	HP-NV
ROTAVP6	Rotavirus	36.3 (25.6- 45.5)	49 (37.5- 58.4)	HP-NEPI- CEPI*
NOROVGRP2	Norovirus	34.2 (24.8- 42.5)	51.9 (40.9- 60.9)	HP-NV

medRxiv preprint doi: https://doi.org/10.1101/2024.01.10.24300883; this version posted January 10, 2024. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

perpetuity. It is made available under a CC-BY-NC-ND 4.0 International license .

CMVPP52	Cytomegalovirus	44.7 (33.5- 54)	54.2 (42.6- 63.5)	HP-NV
MYCPNEU2	Mycoplasma pneumoniae	45.7 (35- 54.6)	56.6 (45.5- 65.4)	HP-NV
COXSACB1	Coxsackie B	40.7 (29.1- 50.4)	58.8 (46- 68.7)	HP-NV
H3N2	Influenza A (H3N2 1999)	37.3 (27- 46.2)	60.9 (49.5- 69.8)	HP-NEPI
SPNEUMO	Streptococcus pneumoniae	45.9 (33.8- 55.7)	64.1 (51.8- 73.3)	HP-NEPI- CEPI*
PFALHSP	Plasmodium falciparum	47 (35.8- 56.2)	69.9 (57.5- 78.6)	HP-NEPI
RSVAF	Respiratory syncytial virus	57.4 (46.9- 70.3)	76.5 (68- 88.8)	HP-NV

451 Table 2

452 Table 2 lists the pathogens assayed and the associated 12- and 24-month seroprevalence for

453 each. The clinical sub-group is denoted beside each target.

454 LP=Low Prevalence, HP-NEPI=High Prevalence-National Expanded Programme on

455 Immunization, EEPI=Established Expanded Programme on Immunization, HP-NV=High

- 456 Prevalence-No Vaccination

469

Figures





- 472 Reverse Kaplan-Meier survival curve demonstrating cumulative antibody prevalence for 473 each target within the panel of infectious diseases pathogens featured on the protein 474 array over a two-year period. The red dots indicate seroprevalence at 12- and 24- months withing the longitudinal cohort. Each curve measures the proportion of population 475 476 infected (Y-axis) with age in days (X-axis).
- 477

478

479



481 Figure 2

482 **Figure 2A.** Antibody trends measured in mean fluorescent intensity (MFI) using linear spline modelling. Aise in MFI levels follow immunization

483 or natural infection. An initial fall of MFI after birth represents maternal antibody decay in targets with high population seroprevalence. A later

484 fall in MFI suggests a waning of antibody response. The vertical green lines indicate timepoints of pentavalent vaccination. Dashed red lines

- 485 represent 95% Cl.
- 486 **Figure 2B.** Reverse Kaplan-Meir plot survival curve demonstrating the cumulative proportion of the cohort responding to immunization or
- 487 exposure to the same targets as fig. 2A over the first two years of life. Red dots indicate 12- and 24-month timepoints. Dashed red lines
- 488 indicate pentavalent vaccination.
- 489





494 Figure 3

495 Figure 3A – Inpatient cohort antibody response to three targets i) influenza H1N1, ii) influenza 496 H3N2, and iii) CMV. Antibody values are measured using mean fluorescent intensity (MFI). 497 The horizontal axis stratifies patients by age in months, up to five years of age. The red triangles denote the mean of the seronegative group in each figure. The dashed red line 498 499 denotes seroconversion, ie two standard deviations above the median antibody level of the 500 seronegative stratum.

501

502 Figure 3B - Horizontal bar chart contrasting both the longitudinal and inpatient cohort specific

503 antibody response. (CI 95%). The pathogens are labelled in code available in Supplementary

504 table 1.

505 Supplementary figures



506 507

508 Supplementary figure 1

509 Time points at which data was collected on each individual patient within the longitudinal cohort recruited between 2002 and 2005. 510

511 The vertical axis uses the study number of each recruit. The first 'x' on the horizontal line 512 designated to each recruit represents cord blood sampling at birth, followed by repeated serum sampling at approximate three-month intervals until children were aged about thirty 513 514 months of age. The y-axis contains anonymized codes that are delinked from personally 515 identifiable participant data.





518 Inpatient cohort comprising of paediatric inpatients admitted to Kilifi County Hospital 519 between 2006 and 2017 with a variety of infectious and non-infectious illnesses. One 520 serological sample was taken at a single time point during admission for medical care. The y-521 axis contains anonymized codes that are delinked from personally identifiable participant 522 data.

523

524



- 525
- 526
- 527

528 **Supplementary figure 3**

529 Supplementary figure 3 illustrates our validation approach using diphtheria toxin, hepatitis B 530 surface antigen, RSV fusion protein and plasmodium falciparum HSP. The serological 531 definition of an infection was an increase of \geq 4000 antibody units (expressed as MFI) between 532 two serial timepoints, and sustained in the subsequent two time points. Each red triangle correlates to the timing of each dose of pentavalent vaccination. The purple triangle indicates 533 534 the timepoint at which natural infection occurred. Panel headings contain anonymized codes that are delinked from personally identifiable participant data. 535



- _ _ _



- 543 Supplementary figure 4
- 544 The design of the microarray chip and the analytical sample workflow.

545 <u>Supplementary table</u>

ID	Pathogen	Strain/subtype	Antigen	Antigen Code
1	Astrovirus	Type 1 strain A88/2	Extract	ASTROVT1
2	Bordetella pertussis		Pertactin	BORDPERT
3	Chikungunya virus		E1	CCHIKVE1
4	Chlamydia pneumoniae		PmpD	CHLAMPNEU
5	Clostridium difficile		GDH	CLOSTDEF
6	Corynebacterium diphtheriae		Diphtheria toxin	DIPHTXN
7	Coxsackie B	B1	VP1	COXSACB1
8	Cytomegalovirus		PP52	CMVPP52
9	Dengue virus	Туре 1	NS1	DENG1NS1
	Dengue virus	Туре 3	NS1	DENG3NS1
	Dengue virus	Туре 4	NS1	DENG4NS1
10	Ebola virus	Zaire strain	NP	EBOVZAIRE
11	Enterovirus 71		Toxin	EV71ETOX
12	Epstein-Barr virus		Nuclear antigen 1	EBV
13	Helicobacter pylori		Hp bacterial antigen	HPYLOR
14	Hepatitis A virus		HAVCR2	HEPAV
15	Hepatitis B virus		Surface antigen AD	HEPBSAGADR
16	Herpes simplex virus	Туре 1	Extract	HSV1EXT
17	Influenza A	A/WSN/1933	Haemagluttinin	H1N1_HA.1933
	Influenza A	A/New Caledonia/20/1999	Haemagluttinin	H1N1_HA.1999
	Influenza A	A/California/07/2009	Haemagluttinin	H1N1_HA.2009
	Influenza A	A/USSR/90/1977	Haemagluttinin	H1N1_HA.1977
	Influenza A	A/Panama/2007/1999	Haemagluttinin	H3N2.1999
	Influenza A	A/Solomon Islands/3/2006	Haemagluttinin	H1N1_HA.2006

ID	Pathogen	Strain/subtype	Antigen	Antigen Code
	Influenza A	A/Brevig Mission/1/1918	Haemagluttinin	H1N1_HA.1918
	Influenza A	A/Puerto Rico/8/1934	Haemagluttinin	H1N1_HA.1934
18	Klebsiella pneumoniae		oMPA	KLEBPNEU
19	Leishmania donovani		AdoMetDC	LEISHDON
20	Mumps virus	Enders	Extract	MUMPSV
21	Mycoplasma pneumoniae	FH	Extract	MYCPNEU2
22	Ngari virus		Extract	NGARIV
23	Norovirus	Type 2	VLP	NOROVGRP2
24	Parvovirus	B19	Antigen 2	PARVO1
25	Plasmodium falciparum	3D7	HSP	PFALHSP
26	Respiratory syncytial virus	Group A	Fusion protein	RSVAF
27	Rift valley fever virus		Glycoprotein	RVFGC
28	Rotavirus	P6	VP6	ROTAVP6
29	Salmonella enterica	Serovar Typhi	H protein	STYPHH
30	Staphylococcus aureus		Alpha Toxin	SAURENTOXA
31	Streptococcus pneumoniae		Pneumolysin	SPNEUMO
32	Tick-borne encephalitis virus		NS1	TBENS1
33	Toxoplasma gondii		H4	TOXOPGON
34	Usutu virus		NS1	USUVNS1
35	Varicella zoster virus	Ellen	Extract	VZV
36	West nile virus		NS1	WNVNS1
37	Yellow fever virus		NS1	YFVNS1A
38	Zika virus		NS1	ZIKVNS1

Supplementary table 1 The complete set of pathogens, strains and antigens that were tested on this platform are listed above.

- 547 Pathogen-specific antibodies were measured using a customized protein microarray designed to quantify serum IgG to a range of common and
- 548 emerging infectious diseases.